Dr. Michael J. Gitlin on Using the Newer Antidepressants
The Carlat Psychiatry Report, Volume 3, Number 1, January 2005
Michael J. Gitlin, M.D.
Professor of Clinical Psychiatry, UCLA School of Medicine
Director of the Mood Disorders Clinic, UCLA Neuropsychiatric Hospital
Dr. Gitlin has disclosed that he is a member of the speakers bureau of Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Astra Zeneca, and Janssen. Dr. Gitlin has disclosed that psychostimulants, modafinil, and T3 have not been approved by the U.S. Food and Drug Administration for use in the treatment of depression.
Please consult product labeling for the approved usages.
Dr. Gitlin, to begin with, my readers would be interested in your impressions of the new kid on the block, Cymbalta (duloxetine).